AC
SGMO

Apex Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Apex Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-439,900
Closed -$4.88M – 52
2015
Q2 		$4.88M Buy
439,900
+39,900
+10% +$514K 0.42% 48
2015
Q1 		$6.27M Buy
+400,000
New +$6.19M 0.45% 52

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Apex Capital's SGMO Position: Q3 2015 in Review

Apex Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2015, closing a stake of 439,900 shares — an estimated $4.88M sold.

Apex Capital first reported a position in SGMO in Q1 2015 and held it in 2 quarters. The position peaked at $6.27M in Q1 2015. 141 funds tracked by Wall St. Rank hold SGMO as of Q3 2015.

  • Apex Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2015 after selling out during the quarter.
  • Apex Capital sold 439,900 SANGAMO THERAPEUTICS INC shares in Q3 2015, an estimated $4.88M.
  • Apex Capital first reported a position in SANGAMO THERAPEUTICS INC in Q1 2015 and held it in 2 quarters.
  • Apex Capital's SANGAMO THERAPEUTICS INC position peaked at $6.27M in Q1 2015.
  • 141 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2015.

Based on Apex Capital's 13F filing for Q3 2015, filed 21 Oct 2015.